2877.HK
2877.HK
KYG2110P1000
SHINEWAY PHARM
Loading chart...

Company Profile

China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; and other dosage forms, including pills and tablets; and traditional Chinese medicine granules in various therapeutic areas, including respiratory system disease, nervous system, digestive system disease, cardiovascular and cerebrovascular, orthopedics, pediatrics, chronic illnesses, and other areas, as well as medication for strengthening the body. It is also involved in the trading of agricultural products. The company was incorporated in 2002 and is headquartered in Shijiazhuang, China. China Shineway Pharmaceutical Group Limited operates as a subsidiary of Forway Investment Limited.

Related stocks

2186.HK
2186.HK • China
LUYE PHARMA
1.73 HKD
880.63M USD 1Y -49.7%
300267.SZ
300267.SZ • China
ER-KANG
3.36 CNY
1.04B USD 1Y -1.8%
300194.SZ
300194.SZ • China
FUAN PHARM
4.03 CNY
717.42M USD 1Y -7.8%
9989.HK
9989.HK • China
HEPALINK
4.03 HKD
752.61M USD 1Y -26.6%
002793.SZ
002793.SZ • China
LUOXINPHARMACEUTICAL
4.89 CNY
795.8M USD 1Y -0.2%
603567.SS
603567.SS • China
HEILONGJIANG ZBD PHARMACEUTICAL
5.4 CNY
759.73M USD 1Y -53.4%
600557.SS
600557.SS • China
JIANGSU KANION PHARMACEUTICAL C
12.4 CNY
1.05B USD 1Y -18.4%
300485.SZ
300485.SZ • China
SCIENCE SUN
8.57 CNY
617.67M USD 1Y -24%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
37.7% p.a.
Max Drawdown (5Y)
-38.5%
Sharpe Ratio (5Y)
-0.05
Beta Factor
0.68
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (37.7% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -74.3% in the extended horizon.
ende